Technology
Choose a subcategory:
Date: March 16, 2010 Time: 9: 30 AM ET Audio Call Dial-In Information: Domestic: 888-462- 6700 International: 970-315- 0485 Passcode: 56696517 Webcast Information: This Webcast can be accessed at Sigma-Aldrich Corporation's web site at http
China Nuokang Bio-Pharmaceutical Inc. is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products.
Pressure BioSciences, Inc. and Target Discovery, Inc. Announce Product Licensing, Manufacturing, Co-
Such forward looking statements include statements regarding the advantages of PCT in processing tissue samples, including the extraction and recovery of intact functional proteins contained in cellular membranes; that the companies will de
For 2010, Bavarian Nordic maintains its financial expectations with revenues in the level of DKK 475 million, a pre-tax loss in the level of DKK 250 million and net free cash and cash equivalents in the range of DKK 225 to DKK 275 million a
Lithera Reports Positive Phase IIa Clinical Study Results for LIPO-102, a Novel Treatment for Locali
SAN DIEGO, March 9, 2010 ( GLOBE NEWSWIRE)- Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate ( SX) and fluticasone propionate ( FP) for sele
DCM is a randomized, controlled, open-label Phase 2 trial which targeted enrollment of 20 patients with ischemic DCM and 20 patients with non-ischemic DCM at five clinical sites in the U.S. Control patients receive standard medical care, wh
See the new video on the Company's patented Vita-Stim ( TM) Stem Cell Nutrition product here http:// video214. com/play/ ie4Gtcm0ncA1RZ8ByDpGFA/s/ dark.
Pluristem Therapeutics Inc. William Prather, RPh, MD, Sr.
A photo accompanying this release is available at http:// www.globenewswire. com/newsroom/ prs/? pkgid = 7191 David Green, President of HBIO, commented, " This bioreactor allows Harvard Bioscience to pursue new opportunities within the emer
NEW YORK, March 8, 2010 ( GLOBE NEWSWIRE)- The NASDAQ Stock Market announced today that it will delist the common stock of Anesiva, Inc. Anesiva, Inc.', s stock was suspended on January 06, 2010 and has not traded on NASDAQ since that time.
This press release contains " forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the belief that these exciting scientific findings will provide further s
Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical tr